Group Leader
Patricia Pozo Rosich
Principal Investigator (PI)
Patricia Pozo Rosich
Researchers
Marta Torres Ferrús, Adrià Vilà Balló, Xim Cerdà Company, Nara Ikumi Montserrat, Marta Vila Pueyo, Erika Ivanna Araya
PhD Students
Alicia Alpuente Ruiz, Angela Barbara Martí Marca, Edoardo Caronna, Victor José Gallardo López
Lab Technicians
Laila Asskour
Nursing and Technical Staff
Eulalia Giné Cipres, Myriam Olivé Díaz, Anna de la Torre Suñé, Victor José Gallardo López, Albert Muñoz Vendrell
33
PUBLICATIONS
413
IMPACT FACTOR
12.52
AVERAGE IMPACT FACTOR
SELECTED ARTICLES
Ashina M, Buse DC, Ashina H, Pozo-Rosich P, Peres MFP, Lee MJ, Terwindt GM, Halker Singh R, Tassorelli C, Do TP, Mitsikostas DD, Dodick DW
Migraine: integrated approaches to clinical management and emerging treatments.
Lancet. 2021 Apr 17;397(10283):1505-1518
DOI: 10.1016/S0140-6736(20)32342-4
IF: 79.323
Ashina M, Katsarava Z, Do TP, Buse DC, Pozo-Rosich P, Özge A, Krymchantowski AV, Lebedeva ER, Ravishankar K, Yu S, Sacco S, Ashina S, Younis S, Steiner TJ, Lipton RB
Migraine: epidemiology and systems of care
Lancet. 2021 Apr 17;397(10283):1485-1495
DOI: 10.1016/S0140-6736(20)32160-7
IF: 79.323
Caronna E, Gallardo VJ, Alpuente A, Torres-Ferrus M, Pozo-Rosich P
Anti-CGRP monoclonal antibodies in chronic migraine with medication overuse: real-life effectiveness and predictors of response at 6 months.
J Headache Pain. 2021 Oct 7;22(1):120
DOI: 10.1186/s10194-021-01328-1
IF: 7.277
Alpuente A, Gallardo VJ, Caronna E, Torres-Ferrus M, Pozo-Rosich P
In search of a gold standard patient-reported outcome measure to use in the evaluation and treatment-decision making in migraine prevention. A real-world evidence study
J Headache Pain. 2021 Dec 13;22(1):151
DOI: 10.1186/s10194-021-01366-9
IF: 7.277
Torres-Ferrus M, Pareto D, Gallardo VJ, Cuberas-Borrós G, Alpuente A, Caronna E, Vila-Balló A, Lorenzo-Bosquet C, Castell-Conesa J, Rovira A, Pozo-Rosich P
Cortical metabolic and structural differences in patients with chronic migraine. An exploratory (18)FDG-PET and MRI study
J Headache Pain. 2021 Jul 17;22(1):75
DOI: 10.1186/s10194-021-01289-5
IF: 7.277
SYNCHRO: Sense, rhYthm & Networks: the study of how erenumab modulates CHROnic migraine.
Principal Investigator: Patricia Pozo Rosich
Agency: Novartis
Funding: 230,000€
Period: 2020-2021
BIOMIGA: A multidisciplinary approach to the identification of BIOmarkers of MIGraine: a proof of concept study based on the stratification of responders to CGRP monoclonal Antibodies.
Principal Investigator: Patricia Pozo Rosich
Agency: Instituto de Salud Carlos III/ERANet Neuron
Funding: 100,000€ VHIR/690,000€ Global
Period: 2020-2022
AhEAD: Algoritmo de predicción de Eficacia de Respuesta A tratamiento preventivo en pacientes con migraña crónica: marcaDores biológicos y clínicos.
Principal Investigator: Patricia Pozo Rosich
Agency: Instituto de Salud Carlos III– ISCIII (FIS)
Funding: 87,120€
Period: 2020-2022
Mecanismos, modulación y terapia del dolor crónico
Principal Investigator: Patricia Pozo Rosich
Agency: Generalitat de Catalunya
Funding: 131,250€
Period: 2020-2022
Neurosciences
- Research group on Status Epilepticus and Acute Seizures
- Neuroradiology
- Stroke Research
- Gene Therapy at Nervous System
- Clinical and Translational Bioinformatics
- Peripheral Nervous System
- Headache and Neurological Pain
- Cell signaling and Apoptosis
- Neurodegenerative Diseases
- Neurotraumatology and Neurosurgery Research Unit (UNINN)
- Clinical Neuroimmunology
- Pediatric Neurology
- Psychiatry, Mental Health and Addictions
- Neuromuscular and Mitochondrial Pathology